Novo Nordisk A/S Rises On Unusually High Volume (NVO)

NEW YORK ( TheStreet) -- Novo Nordisk A/S (NYSE: NVO) is trading at unusually high volume Monday with 634,686 shares changing hands. It is currently at 2.4 times its average daily volume and trading up $3.11 (+2%) at $158.08 as of 10:25 a.m. ET.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Novo Nordisk A/S has a market cap of $86.9 billion and is part of the health care sector and drugs industry. Shares are down 5% year to date as of the close of trading on Friday.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. The company has a P/E ratio of four, below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Novo Nordisk A/S Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade